BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, June 19, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Immuone raises £2M to meet demand for 3D human lung model

Nov. 1, 2023
By Shani Alexander
Immuone Ltd. raised £2 million (US$2.4 million) to fund expansion of its operations to meet growing demand for its 3D human lung model. The company is hoping that its model will replace animal testing which is not always accurate at predicting the impact of drugs on humans. The funding came from the MEIF Proof of Concept & Early Stage Fund, Mercia’s EIS funds and Pioneer Group.
Read More

Financings for Nov. 1, 2023

Nov. 1, 2023
Med-tech firms raising money in public or private financings, including: Covera Health, Genome Insight.
Read More

Financings for Oct. 31, 2023

Oct. 31, 2023
Biopharmas raising money in public or private financings, including: Annovis, Avenue, Biofrontera, Bristol Myers Squibb, Cambrium, Engine, Imagine, Maplight, Mirati, Mustang, Okyo, Sanguine, Scinai, Sellas, Transcode, Vivos.
Read More

Financings for Oct. 31, 2023

Oct. 31, 2023
Med-tech firms raising money in public or private financings, including: Access Vascular, Aqtual, Neteera Technologies, Neuros Medical, Quest Diagnostics, Trinity Capital.
Read More
Photo of Loong Wang, Thong Le and Alice Chen
Drug Design, Drug Delivery & Technologies

Automera launches with $16M series A funding to tackle protein degradation

Oct. 31, 2023
By Tamra Sami
Fledgling biotechnology company Automera has launched in Singapore with $16 million in series A funding to develop its autophagy-targeting chimera small molecules (AUTACs) platform technology. Automera co-founder and chief technology officer Loong Wang told BioWorld that he and his business partner, Taiyang Zhang, decided to move into the biotechnology space in 2021.
Read More

Financings for Oct. 30, 2023

Oct. 30, 2023
Biopharmas raising money in public or private financings, including: Abingworth, Lexeo, Maplight, Meiragtx, Sanofi and Vyne.
Read More

Financings for Oct. 30, 2023

Oct. 30, 2023
Med-tech firms raising money in public or private financings, including: Brainbox.
Read More

Financings for Oct. 27, 2023

Oct. 27, 2023
Biopharmas raising money in public or private financings, including: Faron, Monte Rosa, Mustang, Sandoz, Transcode.
Read More
Photo of Loong Wang, Thong Le and Alice Chen
Drug Design, Drug Delivery & Technologies

Automera launches with $16M series A funding to tackle protein degradation

Oct. 27, 2023
By Tamra Sami
Fledgling biotechnology company Automera has launched in Singapore with $16 million in series A funding to develop its autophagy-targeting chimera small molecules (AUTACs) platform technology. Automera co-founder and chief technology officer Loong Wang told BioWorld that he and his business partner, Taiyang Zhang, decided to move into the biotechnology space in 2021.
Read More
Gold dollar sign

Junction functions fine for Triveni with $92M series A to push atopic dermatitis program

Oct. 26, 2023
By Randy Osborne
The atopic dermatitis space gained another player in Triveni Bio Inc., which pulled down a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management to pay for a proof-of-concept study with lead program, TRIV-509, and boost the Waltham, Mass.-based firm’s broader pipeline.
Read More
Previous 1 2 … 246 247 248 249 250 251 252 253 254 … 678 679 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing